By addressing the underlying biochemical pathway involved in retinal dysfunction, visual cycle modulators have the potential to transform the treatment paradigm for retinopathies caused by insufficient clearance of at-RAL, including STGD1, certain subtypes of rod-cone dystrophies, and other related conditions. The gene discussed is RALA; the disease is Rod-cone dystrophy.